Akorn Inc. | Balance Sheet

Fiscal year is January-December. All values USD Millions.
2013
2014
2015
2016
2017
2018
Cash & Short Term Investments
34
78
352
202
368
226
Total Accounts Receivable
65
188
151
283
141
153
Inventories
56
135
185
175
184
174
Other Current Assets
14
75
20
26
37
31
Total Current Assets
169
476
708
686
730
584
Net Property, Plant & Equipment
82
144
180
238
313
335
Total Investments and Advances
-
-
-
10
-
-
Intangible Assets
160
1,246
1,150
1,043
855
569
Other Assets
9
26
1
1
5
8
Total Assets
432
1,894
2,043
1,974
1,910
1,546
ST Debt & Current Portion LT Debt
-
10
53
-
-
Accounts Payable
23
47
46
60
52
Income Tax Payable
-
-
24
16
16
Other Current Liabilities
38
93
109
100
103
Total Current Liabilities
61
151
231
176
171
Long-Term Debt
109
1,114
994
810
815
Deferred Taxes
2
267
185
152
37
Other Liabilities
2
3
7
11
49
Total Liabilities
172
1,538
1,421
1,155
1,078
Common Equity (Total)
260
356
622
819
831
Total Shareholders' Equity
260
356
622
819
831
Total Equity
260
356
622
819
831
Liabilities & Shareholders' Equity
432
1,894
2,043
1,974
1,910

About Akorn

View Profile
Address
1925 West Field Court
Lake Forest Illinois 60045
United States
Employees -
Website http://www.akorn.com
Updated 07/08/2019
Akorn, Inc. operates as a niche pharmaceutical company that develops, manufactures and markets generic and prescription pharmaceuticals, as well as, animal and consumer health products. It operates through the Prescription Pharmaceuticals and Consumer Health segments. The Prescription Pharmaceuticals segment engages in the sales of generic and branded prescription pharmaceuticals including ophthalmics, injectables, oral liquids, otics, topicals, inhalants, and nasal sprays.